Loading company…
RVAC Medicines develops mRNA and DNA products and provides manufacturing and scale-up capabilities.
RVAC Medicines is a Singapore-based mRNA platform company founded in 2021. It offers GMP manufacturing, process scale-up and technology transfer, and development of single and multi-mRNA or DNA products. In April 2022, it raised USD 140 million in Series B funding led by CBC Group, with EDBI, GS Holdings, and Pavilion Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in